EGFR+ Lung Cancer

Lung Cancer

After reviewing data from a decade of clinical research, a joint panel from ASCO and the College of American Pathologists concluded that circulating tumor DNA testing should be used only to screen for participation in, or during, a clinical trial.

In an interview with<em> Targeted Oncology</em>&nbsp;ahead of the 5th Annual Miami Lung Cancer Conference,&nbsp;Sarah B. Goldberg, MD, discusses&nbsp;the key points of her lecture on testing for and treating resistance to EGFR TKI therapy in NSCLC.

Lung Cancer

The FDA has approved a 4-week dosing schedule for the PD-1 inhibitor nivolumab (Opdivo) across several indications.

NonDriver Metastatic Lung Large Cell Carcinoma

Marina C. Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses current advancements with immunotherapy as first- and second-line treatments for patients with lung cancer.

Joshua Bauml, MD, an assistant professor at Perelman School of Medicine at the University of Pennsylvania, discusses the possibilities with using liquid biopsies in patients with lung cancer.